Skip to main content
Top
Published in: Clinical Pharmacokinetics 11/2021

Open Access 01-11-2021 | Insulins | Original Research Article

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data

Authors: Jennifer Leohr, Mary Anne Dellva, Kallin Carter, Elizabeth LaBell, Helle Linnebjerg

Published in: Clinical Pharmacokinetics | Issue 11/2021

Login to get access

Abstract

Background and Objective

Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This pooled analysis compared the pharmacokinetics and glucodynamics between URLi and Humalog® in healthy subjects and patients with type 1 or type 2 diabetes mellitus.

Methods

The analysis included four randomized, double-blind, crossover, single-dose studies (healthy subjects [n = 74], patients with type 1 diabetes [n = 78], and type 2 diabetes [n = 38]) evaluating subcutaneous doses of 7, 15, or 30 U of URLi and Humalog during an 8- to 10-h euglycemic clamp procedure.

Results

The pooled analysis showed an ~ 5-min faster onset of appearance, an ~8-fold greater exposure in the first 15 min, a 43% reduction in exposure beyond 3 h, and a 68-min shorter exposure duration with URLi vs Humalog across all study populations and dose range. Compared with Humalog, URLi had a 10-min faster onset of action, a 3-fold greater insulin action in the first 30 min, a 35% reduction in insulin action beyond 4 h, and a 44-min shorter duration of action across all populations and dose range. Overall exposure and insulin action were similar between URLi and Humalog for each dose level and study population.

Conclusions

Across the studied populations and dose range, URLi consistently demonstrated a faster absorption, reduced late exposure, and overall shorter exposure duration compared with Humalog. Similarly, URLi demonstrated earlier insulin action while reducing late insulin action and shorter insulin action compared with Humalog across the study populations and dose range.

Clinical Trial Registration

NCT02942654 (registered: 21 October, 2016), NCT03286751 (registered: 15 September, 2017), NCT03166124 (registered: 23 May, 2017), and NCT03305822 (registered: 5 October, 2017).
Literature
1.
go back to reference Ceriello A. Glucose variability and diabetic complications: is it time to treat? Diabetes Care. 2020;43(6):1169–71.CrossRef Ceriello A. Glucose variability and diabetic complications: is it time to treat? Diabetes Care. 2020;43(6):1169–71.CrossRef
2.
go back to reference Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38(8):1610–4.CrossRef Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38(8):1610–4.CrossRef
3.
go back to reference Umpierrez GE, Kovatchev PB. Glycemic variability: how to measure and its clinical implication for type 2 diabetes. Am J Med Sci. 2018;356(6):518–27.CrossRef Umpierrez GE, Kovatchev PB. Glycemic variability: how to measure and its clinical implication for type 2 diabetes. Am J Med Sci. 2018;356(6):518–27.CrossRef
4.
go back to reference American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes: 2020. Diabetes Care. 2020;43(Suppl 1):S14-31.CrossRef American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes: 2020. Diabetes Care. 2020;43(Suppl 1):S14-31.CrossRef
5.
go back to reference Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Diabetes Control and Complications Trial Research Group, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRef Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Diabetes Control and Complications Trial Research Group, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.CrossRef
6.
go back to reference International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103(2):256–68.CrossRef International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103(2):256–68.CrossRef
7.
go back to reference Madsbad S. Impact of postprandial glucose control on diabetes-related complications: how is the evidence evolving? J Diabetes Complications. 2016;30(2):374–85.CrossRef Madsbad S. Impact of postprandial glucose control on diabetes-related complications: how is the evidence evolving? J Diabetes Complications. 2016;30(2):374–85.CrossRef
8.
go back to reference American Diabetes Association. Pharmacologic approaches to glycemic treatment. Standards of medical care in diabetes: 2020. Diabetes Care. 2020;43(Suppl 1):S98–110.CrossRef American Diabetes Association. Pharmacologic approaches to glycemic treatment. Standards of medical care in diabetes: 2020. Diabetes Care. 2020;43(Suppl 1):S98–110.CrossRef
9.
go back to reference Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.CrossRef Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.CrossRef
10.
go back to reference Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab. 2005;31(4 Pt 2):4s7-24.PubMed Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab. 2005;31(4 Pt 2):4s7-24.PubMed
11.
go back to reference Grunberger G. Insulin analogs: are they worth it? Yes! Diabetes Care. 2014;37(6):1767–70.CrossRef Grunberger G. Insulin analogs: are they worth it? Yes! Diabetes Care. 2014;37(6):1767–70.CrossRef
12.
go back to reference Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med. 1996;13(7):625–9.CrossRef Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med. 1996;13(7):625–9.CrossRef
13.
go back to reference Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6(4):728–42.CrossRef Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6(4):728–42.CrossRef
14.
go back to reference Kalra S, Gupta Y. Ultra-fast acting insulin analogues. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(2):117–23.CrossRef Kalra S, Gupta Y. Ultra-fast acting insulin analogues. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(2):117–23.CrossRef
16.
go back to reference Pratt E, Leohr J, Heilmann C, Johnson J, Landschulz W. Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro (abstract 975-P). Diabetes. 2017;66(Suppl 1):A253. Pratt E, Leohr J, Heilmann C, Johnson J, Landschulz W. Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro (abstract 975-P). Diabetes. 2017;66(Suppl 1):A253.
17.
go back to reference Michael M, Zhang C, Siesky A, Cox A, Sperry A, Hansen R, et al. Exploration of the mechanism of accelerated absorption for a novel insulin lispro formulation. Diabetes. 2017;66(Suppl 1):A250. Michael M, Zhang C, Siesky A, Cox A, Sperry A, Hansen R, et al. Exploration of the mechanism of accelerated absorption for a novel insulin lispro formulation. Diabetes. 2017;66(Suppl 1):A250.
18.
go back to reference Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C, et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study. Diabetes Obes Metab. 2020;22(10):1789–98.CrossRef Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C, et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study. Diabetes Obes Metab. 2020;22(10):1789–98.CrossRef
19.
go back to reference Klaff L, Cao D, Dellva MA, Tobian J, Miura J, Dahl D, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020;22(10):1799–807.CrossRef Klaff L, Cao D, Dellva MA, Tobian J, Miura J, Dahl D, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020;22(10):1799–807.CrossRef
20.
go back to reference Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. 2020;43(12):2991–8.CrossRef Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. 2020;43(12):2991–8.CrossRef
24.
go back to reference Haidar A, Duval C, Legault L, Rabasa-Lhoret R. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. J Diabetes Sci Technol. 2013;7(6):1507–12.CrossRef Haidar A, Duval C, Legault L, Rabasa-Lhoret R. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. J Diabetes Sci Technol. 2013;7(6):1507–12.CrossRef
25.
go back to reference Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–5.CrossRef Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–5.CrossRef
26.
go back to reference Krzymien J, Ladyzynski P. Insulin in type 1 and type 2 diabetes: should the dose of insulin before a meal be based on glycemia or meal content? Nutrients. 2019;11(3):607.CrossRef Krzymien J, Ladyzynski P. Insulin in type 1 and type 2 diabetes: should the dose of insulin before a meal be based on glycemia or meal content? Nutrients. 2019;11(3):607.CrossRef
Metadata
Title
Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
Authors
Jennifer Leohr
Mary Anne Dellva
Kallin Carter
Elizabeth LaBell
Helle Linnebjerg
Publication date
01-11-2021
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 11/2021
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-021-01030-0

Other articles of this Issue 11/2021

Clinical Pharmacokinetics 11/2021 Go to the issue